Impacts of combining anti-PD-L1 immunotherapy and radiotherapy on the tumour immune microenvironment in a murine prostate cancer model
Philippou Y., Sjoberg HT., Murphy E., Alyacoubi S., Jones KI., Gordon-Weeks AN., Phyu S., Parkes EE., Gillies McKenna W., Lamb AD., Gileadi U., Cerundolo V., Scheiblin DA., Lockett SJ., Wink DA., Mills IG., Hamdy FC., Muschel RJ., Bryant RJ.
Radiotherapy enhances innate and adaptive anti-tumour immunity. It is unclear whether this effect may be harnessed by combining immunotherapy with radiotherapy fractions used to treat prostate cancer. We investigated tumour immune microenvironment responses of pre-clinical prostate cancer models to radiotherapy. Having defined this landscape, we tested whether radiotherapy-induced tumour growth delay could be enhanced with anti-PD-L1.